Suppr超能文献

一种导致肾性尿崩症的新型血管加压素-2受体突变的鉴定、特征描述及挽救

Identification, characterization and rescue of a novel vasopressin-2 receptor mutation causing nephrogenic diabetes insipidus.

作者信息

Ranadive Sayali A, Ersoy Baran, Favre Helene, Cheung Clement C, Rosenthal Stephen M, Miller Walter L, Vaisse Christian

机构信息

Department of Pediatrics, Division of Endocrinology, University of California San Francisco, San Francisco, CA 94143, USA.

出版信息

Clin Endocrinol (Oxf). 2009 Sep;71(3):388-93. doi: 10.1111/j.1365-2265.2008.03513.x. Epub 2008 Dec 18.

Abstract

OBJECTIVE

X-linked nephrogenic diabetes insipidus (XNDI), caused by mutations in the V2 vasopressin receptor (V2R), is clinically distinguished from central diabetes insipidus (CDI) by elevated serum vasopressin (AVP) levels and unresponsiveness to 1-desamino-8-d-arginine vasopressin (DDAVP). We report two infants with XNDI, and present the characterization and functional rescue of a novel V2R mutation.

PATIENTS

Two male infants presented with poor growth and hypernatraemia. Both patients had measurable pretreatment serum AVP and polyuria that did not respond to DDAVP, suggesting NDI. However, both also had absent posterior pituitary bright spot on MRI, which is a finding more typical of CDI.

METHODS

The AVPR2 gene encoding V2R was sequenced. The identified novel missense mutation was re-created by site-directed mutagenesis and expressed in HEK293 cells. V2R activity was assessed by the ability of transfected cells to produce cAMP in response to stimulation with DDAVP. Membrane localization of V2R was assessed by fluorescence microscopy.

RESULTS

Patient 1 had a deletion of AVPR2; patient 2 had the novel mutation L57R. In transiently transfected HEK293 cells, DDAVP induced detectable but severely impaired L57R V2R activity compared to cells expressing wild-type V2R. Fluorescence microscopy showed that myc-tagged wild-type V2R localized to the cell membrane while L57R V2R remained intracellular. A nonpeptide V2R chaperone, SR121463, partially rescued L57R V2R function by allowing it to reach the cell membrane.

CONCLUSIONS

L57R V2R has impaired in vitro activity that can be partially improved by treatment with a V2R chaperone. The posterior pituitary hyperintensity may be absent in infants with XNDI.

摘要

目的

X连锁肾性尿崩症(XNDI)由血管加压素V2受体(V2R)突变引起,临床上与中枢性尿崩症(CDI)的区别在于血清血管加压素(AVP)水平升高以及对1-去氨基-8-D-精氨酸血管加压素(DDAVP)无反应。我们报告了两名XNDI婴儿,并介绍了一种新型V2R突变的特征及功能挽救情况。

患者

两名男婴出现生长发育迟缓及高钠血症。两名患者治疗前血清AVP均可测,且存在对DDAVP无反应的多尿症状,提示为尿崩症。然而,两人MRI检查均显示垂体后叶亮点缺失,这一表现更常见于CDI。

方法

对编码V2R的AVPR2基因进行测序。通过定点诱变重新构建鉴定出的新型错义突变,并在HEK293细胞中表达。通过转染细胞对DDAVP刺激产生环磷酸腺苷(cAMP)的能力评估V2R活性。通过荧光显微镜评估V2R的膜定位。

结果

患者1存在AVPR2缺失;患者2有新型突变L57R。在瞬时转染的HEK293细胞中,与表达野生型V2R的细胞相比,DDAVP诱导可检测到但严重受损的L57R V2R活性。荧光显微镜显示,带有myc标签的野生型V2R定位于细胞膜,而L57R V2R仍保留在细胞内。一种非肽类V2R伴侣分子SR121463通过使L57R V2R到达细胞膜,部分挽救了其功能。

结论

L57R V2R体外活性受损,用V2R伴侣分子治疗可部分改善。XNDI婴儿可能不存在垂体后叶高强度信号。

相似文献

1
Identification, characterization and rescue of a novel vasopressin-2 receptor mutation causing nephrogenic diabetes insipidus.
Clin Endocrinol (Oxf). 2009 Sep;71(3):388-93. doi: 10.1111/j.1365-2265.2008.03513.x. Epub 2008 Dec 18.
2
V2 vasopressin receptor (V2R) mutations in partial nephrogenic diabetes insipidus highlight protean agonism of V2R antagonists.
J Biol Chem. 2012 Jan 13;287(3):2099-106. doi: 10.1074/jbc.M111.268797. Epub 2011 Dec 5.
3
Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus.
Am J Physiol Renal Physiol. 2007 Jan;292(1):F253-60. doi: 10.1152/ajprenal.00247.2006. Epub 2006 Aug 22.
7
A novel AVPR2 splice site mutation leads to partial X-linked nephrogenic diabetes insipidus in two brothers.
Eur J Pediatr. 2016 May;175(5):727-33. doi: 10.1007/s00431-015-2684-4. Epub 2016 Jan 21.
10
Diverse vasopressin V2 receptor functionality underlying partial congenital nephrogenic diabetes insipidus.
Am J Physiol Renal Physiol. 2009 Dec;297(6):F1518-25. doi: 10.1152/ajprenal.00331.2009. Epub 2009 Oct 7.

引用本文的文献

1
Central Diabetes Insipidus in Father and Son Linked to a Rare Variant: A Case Report.
Biomed Hub. 2025 Feb 7;10(1):57-63. doi: 10.1159/000543795. eCollection 2025 Jan-Dec.
2
Severe Hypernatremia in an Adolescent With Anorexia Nervosa.
Clin Pediatr (Phila). 2021 Dec;60(14):586-590. doi: 10.1177/00099228211055283. Epub 2021 Oct 27.
3
EJE AWARD 2019: New diagnostic approaches for patients with polyuria polydipsia syndrome.
Eur J Endocrinol. 2019 Jul;181(1):R11-R21. doi: 10.1530/EJE-19-0163.
4
How genetic errors in GPCRs affect their function: Possible therapeutic strategies.
Genes Dis. 2015 Jun;2(2):108-132. doi: 10.1016/j.gendis.2015.02.005.
5
X-Linked Recessive form of Nephrogenic Diabetes Insipidus in a 7-Year-Old Boy.
Balkan J Med Genet. 2015 Apr 10;17(2):81-5. doi: 10.2478/bjmg-2014-0078. eCollection 2014 Dec.
6
Central vasopressin: dendritic and axonal secretion and renal actions.
Clin Kidney J. 2014 Jun;7(3):242-7. doi: 10.1093/ckj/sfu050. Epub 2014 May 23.
7
Oligomerisation of C. elegans olfactory receptors, ODR-10 and STR-112, in yeast.
PLoS One. 2014 Sep 25;9(9):e108680. doi: 10.1371/journal.pone.0108680. eCollection 2014.
8
9
Global analysis of the effects of the V2 receptor antagonist satavaptan on protein phosphorylation in collecting duct.
Am J Physiol Renal Physiol. 2014 Feb 15;306(4):410-21. doi: 10.1152/ajprenal.00497.2013. Epub 2013 Nov 20.
10
Nephrogenic diabetes insipidus: essential insights into the molecular background and potential therapies for treatment.
Endocr Rev. 2013 Apr;34(2):278-301. doi: 10.1210/er.2012-1044. Epub 2013 Jan 29.

本文引用的文献

2
The diagnosis of children with central diabetes insipidus.
J Pediatr Endocrinol Metab. 2007 Mar;20(3):359-75. doi: 10.1515/jpem.2007.20.3.359.
3
Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus.
J Am Soc Nephrol. 2006 Jan;17(1):232-43. doi: 10.1681/ASN.2005080854. Epub 2005 Nov 30.
4
Nephrogenic syndrome of inappropriate antidiuresis.
N Engl J Med. 2005 May 5;352(18):1884-90. doi: 10.1056/NEJMoa042743.
5
Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein.
Nat Biotechnol. 2004 Dec;22(12):1567-72. doi: 10.1038/nbt1037. Epub 2004 Nov 21.
6
Pharmacological chaperone action on G-protein-coupled receptors.
Curr Opin Pharmacol. 2004 Oct;4(5):528-33. doi: 10.1016/j.coph.2004.08.001.
8
Pharmacological chaperones: potential treatment for conformational diseases.
Trends Endocrinol Metab. 2004 Jul;15(5):222-8. doi: 10.1016/j.tem.2004.05.003.
10
Diabetes insipidus.
Rev Endocr Metab Disord. 2003 May;4(2):177-85. doi: 10.1023/a:1022946220908.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验